(Reuters) - By Ben Hirschler, European Pharmaceuticals Correspondent
LONDON, June 22 - Europe accelerated its adoption of so-called biosimilar medicines on Friday as an expert panel recommended the approval of three cut-price versions of epoetin alfa, or EPO, for treating anaemia.
Read more at Reuters.com Government Filings News
LONDON, June 22 - Europe accelerated its adoption of so-called biosimilar medicines on Friday as an expert panel recommended the approval of three cut-price versions of epoetin alfa, or EPO, for treating anaemia.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment